How is AI integration transforming diagnostic imaging and IVD, sustaining above-sector premium device growth?

AI-powered diagnostic imaging — CT, MRI, and digital pathology with deep learning reconstruction, automated lesion detection, and radiology workflow prioritisation — is sustaining premium capital equipment demand from hospital system investment in AI-augmented diagnostic infrastructure. FDA AI/ML-enabled medical device approvals — exceeding 1,000 cleared algorithms by 2025 — are sustaining structured procurement from radiology departments, pathology laboratories, and cardiology centres implementing AI-assisted interpretation tools that demonstrably reduce diagnostic error and radiologist workload at qualifying health system accounts.

What minimally invasive surgery adoption trajectory is sustaining robotic surgical system and disposable demand?

Robotic-assisted minimally invasive surgery (RAMIS) — laparoscopic, thoracoscopic, and urological procedures using Intuitive da Vinci, Medtronic Hugo, CMR Surgical Versius, and competing platforms — is sustaining exceptional capital equipment and disposable instrument demand from surgical volume conversion from open to robotic-assisted across general surgery, gynaecology, urology, and cardiothoracic specialties. Each robotic system placement sustains multi-year disposable instrument, drape, and accessory revenue streams above the upfront capital transaction.

How is continuous glucose monitoring and diabetes care device growth sustaining above-sector IVD expansion?

Continuous glucose monitoring (CGM) systems — Abbott FreeStyle Libre, Dexterity G7, and Medtronic Guardian — sustaining structural device revenue growth from the global Type 1 and Type 2 diabetes prevalence expansion and the clinical and payer shift from episodic fingerstick glucose testing to real-time 24-hour glucose profile monitoring. CGM subscription model revenue from sensor replacement and app ecosystem sustains recurring above-capital-equipment revenue growth at Abbott, Dexterity, and CGM platform competitors.

What home healthcare device expansion is sustaining care decentralisation investment post-pandemic?

Remote patient monitoring (RPM) devices — cardiac implantable loop recorders, wearable ECG patches, continuous blood pressure monitors, home spirometers, and connected vital sign monitoring platforms — sustaining above-facility-based device revenue growth from hospital-at-home programmes, integrated care pathway investment, and CMS Acute Hospital Care at Home reimbursement frameworks enabling hospital-grade monitoring in domiciliary settings. Growing payer support for RPM reimbursement sustains structured home device procurement at integrated health system and home health agency accounts.

How is emerging market healthcare infrastructure investment sustaining medical device demand above developed-market growth?

India’s Ayushman Bharat health insurance expansion covering 500 million beneficiaries, China’s Healthy China 2030 hospital bed and diagnostic equipment investment, Southeast Asian hospital infrastructure development from growing middle-class healthcare demand, and Middle Eastern Vision 2030 hospital network construction are sustaining emerging market medical device demand growth above developed-market replacement cycle baseline. Global OEM emerging market localisation — Siemens Healthineers, GE HealthCare, and Philips regional manufacturing — is sustaining competitive device positioning in price-sensitive emerging market procurement environments.

Which medical device segments are growing fastest?

AI-integrated diagnostic imaging and IVD from clinical decision support investment, robotic-assisted minimally invasive surgery from RAMIS adoption, continuous glucose monitoring from diabetes management digitalisation, remote patient monitoring from care decentralisation, and emerging market hospital infrastructure equipment from developing healthcare system expansion are the five fastest-growing medical device segments.